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Abstract

The Relationship of Chlamydia antigen, AD-like pathology, and Inflammation in
the brains of intranasally infected BALB/c mice

Brittany L. Kane
MS in Biomedical Sciences August 2015
Depmiment of Pathology, Microbiology, Immunology and Forensic Medicine
Philadelphia College of Osteopathic Medicine, Philadelphia, PA
C. Scott Little, Ph.D. Thesis Advisor
Alzheimer's' Disease (AD) is a progressive neurodegenerative disease that affects
millions of elderly individuals in the westem world. There are two f01ms of AD, sporadic
late-onset AD and Familial AD. The neuropathy seen in both cases of AD is the same;
neurofibrillary tangles (NFTs) that are composed of modified tau protein, and nemitic
senile plaques (NSPs) composed of deposited beta amyloid peptide. The objective of this
study is to continue to investigate the role of infection as a possible risk factor for
sporadic AD. Previous mouse models using Chlamydia pneumoniae demonstrated that
intranasal inoculation with this organism induced AD-like pathology in mouse brain
tissue { {17 Little,C.S.( 1) 2004;} }. Previous studies examined non-transgenic BALB/c
mice that were intranasally inoculated with an in vivo passaged isolate of C. muridarum
(C small Weiss) and a stock isolate of C. muridarwn (mouse pneumonitis Weiss), a
mouse adapted respiratory isolate of C. trachoma tis. The presence of C. m.uridarum
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antigen as well as deposited beta amyloid was established at the 60-day time point. The
goal of this study was to detetmine whether astrocyte activation would be identified
within brain tissue previously verified with infection of C. muridarum and deposited beta
amyloid. Based on previously observed AD-like pathology, it was hypothesized that
astrocytes will respond to infection and deposited beta amyloid and become activated. At
the 2 month time point, Semiquantitative, immunohistochemical and microscopic
analysis revealed great variability in glial cell specific labeling in mice intrasnasally
inoculated with either isolate of C. muridarum. Analysis of the stock isolate of C.
muridarum revealed an approximate 3-fold increase between the titer negative group and

the titer positive 1:20480 expetimental group. Analysis of the in vivo passaged isolate
displayed less than a 10% difference in total glial cell number between the titer negative
and the titer positive 1:10240 experimental group. These data indicate that intranasal
infection with C. muridarum induces glial cell activation in the brains ofBALB/c mice.
However these data suggest that the degree of activation is dependent on the isolate of C.
muridarum introduced. The initial hypothesis proposed that glial cell burden would

increase in response to chlamydia infection and amyloid pathology. However, an inverse
con-elation between glial cell count and amyloid deposit burden was noted in both
isolates of C. muridarum, although there was a considerably greater inverse con·elation
between glial cell count and amyloid burden in the mouse pneumonitis Weiss stock
group. In accordance with the initial hypothesis, as chlamydia antigen burden increased,
glial cell counts also increased in the C small Weiss group. However, the relationship of
glial cells and chlamydia antigen burden differed from the initial hypothesis for the
mouse pneumonitis Weiss group. As chlamydia antigen burden increased, glial cell
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counts decreased. These data suggest that the in vivo passaged C small Weiss isolate is
more virulent than the stock passaged mouse pneumonitis Weiss isolate of C. muridarum.
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1. Introduction

1.1 Alzheimer's Disease Prevalence and Significance
Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of elderly
individuals in the western world (1). The prevalence of this disease increases with age
and is believed to affect between 24% and 33% of people that are over the age of85 (2).
According to cunent estimates, there are 24 million cases of AD worldwide and it
accounts for 50-60% of all cases of dementia.

1.2 Signs and Symptoms of AD
Alzheimer's Disease is characterized by a progressive loss of cognitive function
caused by degeneration in the medial temporal lobe, which eventually spreads through
the limbic system to the association and primary cortices (3). Neurodegeneration
associated with AD is believed to begin 20-30 years before clinical onset, and is
classified as the preclinical phase. As first symptoms appear, the condition is often
described as mild cognitive impaitment (MCI) (2) . The first areas affected are the
regions involved in the processing and storage of new memory, the hippocampus and the
entorhinal cortex (4). Individuals at this stage experience more memory problems than
normal for people their age, yet the impairment with MCI is not as severe as that seen in
AD (5). A decline in cognitive processes such as word finding, visual/spatial issues, and
problems with judgment or reasoning, are symptoms characteristic ofMCI progressing to
mild AD. Mild AD is associated with memory loss and a decline in other cognitive
abilities as well as mood and personality changes, repeating questions, and taking longer
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to complete a daily task (6). As the disease progresses to moderate AD, damage occurs
in areas of the brain responsible for language, reasoning, sensory processing and
conscious thought. At this stage, memory loss worsens and patients may have difficulty
leaming new things and recognizing fi·iends and family. As the disease progresses to
severe AD, plaques and tangles have spread tlu·oughout the brain. People at tllis stage
cannot c01mnunicate and are entirely dependent on others for their care (6).

1.3 Alzheimer's Disease Pathogenesis and Pathology
There are two fonns of AD, sporadic late-onset AD and Familial AD. The
neuropathology seen in both cases of AD is the same; neurofibrillary tangles (NFTs) that
are composed of modified tau protein, and neuritic senile plaques (NSPs) composed of
deposited beta amyloid peptide (7). Beta amyloid deposition is believed to play a role in
the neuronal degeneration seen in AD.
Familial AD is caused by genetic mutations that lead to pathology (1) . The first
mutation identified to cause the familial form of the disease is the amyloid precursor
protein (APP) gene on chromosome 21. The protein is digested by proteases near the
carboxyl-tenninus leading to the production of beta amyloid. Mutation on the APP gene
is associated with increased deposition of beta amyloid. Genes encoding for
transmembrane proteins presenilin-1 (PS-1) and presenilin-2 (PS-2) are also involved in
the development of the familial f01m of AD. Mutations in these genes also lead to
increased beta amyloid deposition and are responsible for most of the familial cases (2,
8). However, the familial fonn of this disease is rare.
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Sporadic AD is much more prevalent than familial AD and its exact cause is still
unknown. The occunence of sporadic AD increases with age and is the most common
fonn of senile dementia (1). CmTently, the only genetic factor that con·elates with the
sporadic fonn of AD is the possession of the E4 allele type at the apolipoprotein E (apoE)
locus on chromosome 19 (1) . ApoE is a major protein of the lipoprotein transfer system
and plays a pivotal role in lipid transport in circulation. ApoE also plays a major role
outside of the CNS in atherosclerosis and dyslipidemia (9). In the brain, apoE is
synthesized primatily by astrocytes, although microglia and neurons also play a minor
role in the synthesis of the lipoprotein. Possession of the E4 allele does not necessarily
mean the individual will develop AD. However, its presence is associated with an
increased tisk of developing sporadic AD and contributes to an earlier onset of the
disease as well as a more rapid disease progression (1). Individuals heterozygous for the
e4 allele have a three-fold increase in risk for sporadic AD and homozygotes have a 1218 fold highertisk (10).

1.4 Amyloid Cascade Hypothesis
One hypothesis for the onset of AD is the amyloid cascade hypothesis (11). It
states that presence of beta amyloid, a main component of senile plaques, is the initiating
event, leading to neuronal degeneration, neurofibrillary tangles, vascular damage, and
cognitive impainnent eventually progressing to dementia (11). The mutation associated
with familial AD suppotis this hypothesis in that it is caused by mutations for both the
amyloid precursor protein (APP) and the presenilin-1 and presenilin-2 gene, leading to
increased beta amyloid deposition. People with Down's syndrome who possess an extra
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APP gene develop beta amyloid plaques early in life (12) . This suppmis the hypothesis
that overexpression of APP leads to deposition of beta amyloid. It was once believed that
beta amyloid was an abnonnal protein found only in senile plaques, however, it was
discovered that beta amyloid is produced dming nmmal cell metabolism, and is cleaved
from APP by P-secretase and Y-secretase (2). Soluble beta amyloid is believed to fonn
beta-pleated sheets, which eventually deposit to fonn plaques (2). Severity of disease in
familial AD correlates directly with amount ofbeta amyloid deposition. This is not
always the case with sporadic AD. However, aggregations of amyloid plaques may be
observed in cases of sporadic AD, as well as cognitively nonnal aged individuals. In
individuals that progress to AD, the amyloid cascade hypothesis suggests that beta
amyloid leads to neuronal degeneration and may also be the initiating factor in the
inflammatory cascade that is seen in AD.

1.5 Neuro-inflammation in AD

The presence of inflammation at sites of amyloid plaques and neurofibrillary
tangles has been observed in pathology of AD. Microglia, the resident macrophages of
the central nervous system, work to clear beta amyloid from the CNS by phagocytizing
and internalizing the protein (13). Microglia produce nitric oxide, reactive oxygen
species (ROS), pro-inflatmnatory cytokines, and prostaglandins in the presence of beta
amyloid (14). Astrocytes are the most abundant glial cells in the human brain and have
more specialized functions than microglia. Namely, astrocytes act as suppmiive cells to
the endothelial cells of the blood brain barrier, supply nuttients to nervous tissue,
maintain the extracellular ion balance, and assist in healing and repairing the brain and
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spinal cord following traumatic injury (15). Similar to microglia, astrocytes also secrete
various pro-inflammatory molecules such as interleukins, prostaglandins and complement
factors, and may become activated by nearby activated microglia as a "bystander effect"
(13, 15). In addition to the previously described functions, astrocytes play a direct role in

the deposition and clearance of beta amyloid. This results in a positive feedback loop for
the generation of amyloid (13) . Neurons were once thought to not play a role in
neuroinflammation. However, it was recently discovered that neurons contribute to the
production ofneuroinflammatory products in AD (15) . Neurons also produce several
chemokines and cytokines, such as IL-l, IL-6 and TNF-alpha. Specific chemokines
produced by neurons actually act as messengers between neurons and glial cells such as
macrophage-inflmmnatory protein 1-a, monocyte chemoattractant protein-1, and
macrophage colony stimulating factor (15, 16). Therefore, it is hypothesized that the
deposition of beta amyloid may stimulate the inflatmnatory response that is initiated by
the activation of glia. Secretion of pro-inflammatory substances, including IL-l, IL-6,
and TNF-alpha by activated glia may lead to neuronal degeneration and eventually cell
death (17) .
IL-l is an immunoregulatory cytokine that is overexpressed early in plaque
fonnation and is believed to be the most important cytokines in AD (18-20) . IL- l may
promote the synthesis and processing of APP, thereby promoting the production and
deposition of amyloid into plaques (18, 19). IL-l is also believed to promote SlOO beta
overexpression, a neurite growth promoting cytokine that is produced by reactive
astrocytes (I 8) .
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IL-6 is a proinflammatory cytokine that induces acute phase proteins (a class of
proteins whose plasma concentration increases or decreases in response to inflammation),
acts as a pyrogen, and increases vascular permeability, lymphocyte activation, and
antibody synthesis (18). In mice, elevated levels ofiL-6 have been shown to cause CNS
damage and behavioral deficits. Levels of IL-6 have also been shown to be increased in
the brain of AD patients (19). IL-6 may also play a role in APP synthesis, as well as
transcription and expression of this protein (18)
After exposure to beta amyloid, TNFa has been shown to be elevated in AD
semm, CSF, cortex and glial cell cultures and is repmted to kill human cmtical neurons
when in excess (18, 19). TNFa produces its effects tlu·ough two receptors, the p55 TNF
receptor and the p75 TNF receptor. The p55 TNF receptor is believed to have an
intracellular "death domain" that contributes to cell death when activated. In contrast, the
p75 TNF receptor plays a protective role in neuronal survival. The expression ratio ofthe
two TNFa receptors may regulate neuronal death and survival (18, 20).
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Figure 1: Cytokines hypothesis ofneuroinflammation (Singhal eta!., 2014)

Although these inflammatory events are initiated in response to deposited beta amyloid,
the stimulus for beta amyloid deposition is still unknown.

1.6 Infection in AD
It has been proposed that infection could possibly initiate the inflmmnatory

cascade of AD (8). A number of microbes have been studied as tisk factors in the
development of AD, including Borrelia burgd01jeri, Helicobacter pylori (H. pylori), and
Chlamydia pneumoniae (C. pneumoniae). Herpes simplex vims 1 (HSV-1) has been

suggested as a risk factor for the development of AD in people expressing the apoE e4
(8).
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1.6.1 Herpes Simplex-]
HSV-1 is a common virus affecting between 40-80% of people worldwide (21).
Although it typically infects the oro facial region, HSV -1 is also implicated in keratitis,
genital herpes, and encephalitis (21). HSV -1 establishes a life-long infection in the
peripheral nervous system of most individuals after primary infection (22). HSV-1 may
enter the brain and cause a latent infection that reactivates sporadically in the same
regions that are implicated in AD. This virus enters nerve ganglia through axonal
retrograde transpmi and reactivates periodically to cause recurrent infections at the initial
infection site (21) . Animal studies found that latent intranasal or corneal infection with
HSV -1 was associated with focal chronic inflammation and oxidative damage in the brain

(22). Intracerebral injection of this virus also led to encephalitis and death (22).
Viral DNA was found to be associated with amyloid plaques in the brains of AD
patients (21). Another study also showed that beta amyloid deposits are present in the
mouse brain after HSV-1 infection, fmiher supporting HSV-1 infection as a causative
agent in AD (23). Combined, these studies provide evidence that HSV-1 can cause a
clu·onic latent infection in the human brain tlu·ough the nasal route, and cause clu·onic
inflammation like that observed in AD.

1.6.2 Spirochetes
Spirochetes are fi·ee-living or host-associated helical gram-negative bacteria that
cause latent infection in humans. A study by Miklossy and coworkers found unidentified
spirochetes in the blood, CSF, and brains of 14 AD patients that were absent in controls

(22, 24). They found Borrelia burgd01jeri, a type of spirochete that causes Lyme disease,
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co-localized with beta amyloid deposits (22, 24). Another study showed that introducing
neuronal and glial cells to Borrelia burgd01jeri and its lipopolysaccharide in vitro caused
an increase in beta amyloid and hyper-phosphorylated tau (22, 23). These studies indicate
that infection with this bacterium may trigger the fonnation and deposition of beta
amyloid, and this event may lead to the amyloid plaques that are seen in AD.

1.6.3 Helicobacter pylori
Helicobacter pylori are gram-negative bacte1ia that colonize the gastric mucosa.
H pylori has been linked with various digestive diseases, and is the causative agent of

peptic ulcer disease. Vascular disorders caused by vascular dysregulation, atherosclerosis,
hypertension, cardiovascular and/or cerebrovascular ischemia, and stroke has also been
associated with H pylori (25). These conditions impair the blood brain barrier and,
therefore, are all risk factors for AD.

1.6.4 Chlamydia pneumoniae
Another bacterium that causes inflammation and has been implicated in AD, is
Chlamydia pneumoniae (7). C. pneumoniae is an obligate intracellular bacterium that

infects the oral and respiratory mucosa. This organism is seen in common respiratory
infections such as bronchitis and sinusitis, and also in severe, chronic infections such as
chronic obstmctive pulmonary disease (COPD) (26, 27) .
As with all species of Chlamydia, C. pneumoniae undergoes a biphasic
development cycle during growth. Bacterial multiplication of all species of chlamydia
occurs within a vacuole or 'inclusion' (28). The first stage of development is called the
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elementary body (EB), and is the infectious, extracellular form of the bacterium. The EB
typically infects epithelial cells, however, it can also infect astrocytes, microglia, and
neurons (29). The EB attaches to a host cell by electrostatic binding and is taken into the
cell by endocytosis. Within the cell, the EB stays within a phagosome, and then enters the
reticulate body (RB) stage, in which it becomes metabolically active (29, 30). The RB
will undergo many rounds of cell division via binary fission before the active stage ends,
taking about 2-3 days, and enter back into the EB fonn (29, 30). The EB fonn then exits
the host cell via lysis or exocytosis and the infection continues, leaving the host cell
intact. This process allows the bacterium to cause a silent, chronic infection. Chlamydia
species may leave the replicative life cycle and enter a persistent state in response to
specific host stimuli (30). These stimuli include treatment with specific cytokines such as
interferon-gamma, which is induced as a result of pro-inflatmnatory cytokine production,
antibiotics, or a restriction of nutrients. In this state, metabolic activity is reduced and the
organism does not respond to antibiotics (30). In several studies, chronic persistent
infections of C. pneumoniae in vascular cells led to pro-proliferative and proinflammatory phenotypes within the affected vasculature. Attempts to eliminate this
organism in patients with cardiovascular disease were not successful. This indicates that
the persistent state of Chlamydia is refractory to antibiotic treatment (31). This is
important because it allows the bacterium to avoid itmnune system attack. Research
conducted by Hatmnerschlag et al (2000) discovered persistent infection with C.
pneumoniae after acute respiratory infection in five patients in a peliod of up to 11

months, despite treatment with multiple courses of antibiotics, and two of these five
patients displayed persistence for 7-9 years (27). Organisms in the persistent state elicit
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chronic disease, such as chronic pulmonary diseases. C. pneumoniae can also disseminate
and promote chronic inflammation at sites not associated with the respiratory tract, such
as the cardiovascular system and the central nervous system (29) .
Persistence of the organism has been observed in both human isolates of
chlamydia, Chlamydia trachomatis and Chlamydia pneumoniae. C. trachomatis is the
most common sexually transmitted infection worldwide and is the main cause of
preventable blindness (1 8). Similar to C. pneumoniae, infection of epithelial cells with C.
trachomatis elicits an inflammatory response. Although clearance of this organism

through inflammation is usually successful, some individuals can develop clu·onic
inflammation leading to tissue damage (18). C. trachomatis infection has been
implicated in inflatmnatory diseases such as ReA, pelihepatitis, and pelvic inflammatory
disease (32-34) . Both ReA and perihepatitis provide evidence for the ability of this
organism to disseminate from its site of primary infection. Monocytes may phagocytose
this bacterium and catTy it to sites distant fiom the site of infection (33) . Ifthe organism
has the ability to infect the joints after genito-urinary infection, then it not only can cause
joint inflatmnation, but can also disseminate to other sites. This affect was observed in a
rat model in which there was significant dissemination of C. trachomatis from the joints
to the liver and spleen (35) . The ability of C. trachomatis to disseminate throughout the
body would be necessary for this organism to infect brain tissue and possibly cause AD
pathology.
Chlamydiallipopolysaccharide (LPS), heat shock proteins, and outer membrane
proteins cause the inflammatory response (29). Infection with this organism also may up
regulate cytokine production in neighboring cells. Pro-inflammatory cytokines associated
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with chlamydia! infection include IL-l~, TNFa, IL-6, and IL-8 (8, 36). IFN-Y and IL-12
were also found at sites of chlamydia! infection. Chlamydia! infection may cause the
inflammatory response directly by up regulating cytokine production, or the immune
response to infected cells may drive inflammation through cytokine producing
macrophages/lymphocytes (8, 29) The inflammatory cytokines and chemokines are
known to recmit neutrophils and other leukocytes. Neutrophils destroy accessible EBs
and release matlix metalloprotease (MMPs) molecules and neutrophil elastase, which
lead to tissue damage (36). The fact that chlamydia can generate a persistent infection
and promote an inflammatory response fmiher suppmis the hypothesis that infection with
Chlamydia pneumoniae may play a role in the development of sporadic AD (7).

1.7 Chlamydia pneumoniae and Accompanying Pathologies
C. pneumoniae is able to infect a wide variety of eukaryotic cell types, and almost

all people will be infected with this bacterium by the age of 20. Reinfection is cmmnon;
with a higher antibody count in older populations (1 7). As previously stated, this
organism is known to cause acute respiratory infections, such as pneumonia, sinusitis and
bronchitis. C. pneumoniae has also been implicated in chronic respiratory diseases, such
as asthma, sarcoidosis, and chronic obstmctive pulmonary disease (8, 17). C.
pneumoniae has been associated with non-respiratory diseases, including atherosclerosis,
reactive mihritis, multiple sclerosis, as well as several diseases affecting the central
nervous system (7, 8, I 7). In a study by Hannu et al, (1999) 35 of 60 patients had reactive
arthritis with evidence of a preceding infection with C. pneumoniae. Additionally, four
ReA patients had serological evidence of recent C. pneumoniae infection and three ofthe
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four patients had recent symptoms of a lower respiratory infection that preceded mth1itis

(37) .

C. pneumoniae has been identified in atheromatous plaques in the carotid, a01ta
and coronary mteries of people with coronary syndrome (7, 38). C. pneumoniae may
exacerbate atherosclerosis by activating toll-like receptors on macrophages and dendritic
cells (DCs) that populate the aortic sinus in these patients. C. pneumoniae can both
induce the inflammatory process and intensify the existing inflammatory process in the
a01tic sinus (38).
In another study by Sriram, et al, (1999) C. pneumoniae infection was found in
patients with newly diagnosed relapsing-remitting MS as well as in patients with
progressive MS, but was not found in control patients with other neurological disease.
64% (24 of37) of these patients were positive for C. pneumoniae in the CSF. This
organism was found in both relapsing-remitting MS and progressive MS providing
evidence that infection of the CNS occurs early and persists throughout the course of the
disease (39). The fact that C. pneumoniae is implicated in these diseases provides
evidence that this organism is found at sites other than the site of primary infection. This
research indicates that C. pneumoniae can disseminate systemically and cause infection at
sites other than the respiratory epithelium.

1.7.1 Chlamydia pneumoniae and Alzheimer's Disease
The first study associating C. pneumoniae infection with AD pathology
discovered chlamydia genetic material through PCR analysis in 90% (17 of 19) of LOAD
brains post mortem. In contrast, 18 of 19 control samples were PCR negative for this
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genetic material. Regions implicated in AD, including hippocampus, temporal cmiex and
prefrontal cmiex were positive for C. pneumoniae (7, 29). Fmihennore, immunolabeling
identified this organism within pericytes, microglia, and astroglia, and these cells colocalized with both amyloid plaques and neurofibrillary tangles (1, 8). These findings
were also consistent with the apoE genotype as a risk factor for the development of
sporadic AD. The majority of patients who were PCR positive for chlamydia antigen
possessed at least one 84 allele. Four patients with chlamydia} DNA in the temporal lobe,
prefrontal coliex, and cerebellum displayed the most severe neuropathology, and tlu·ee of
these four patients had an 84 allele (7, 8). Cytokine expression was also up regulated as a
result of chlamydia infection, which can induce chlamydia to enter into a persistent state
and lead to a prolonged inflanunatory response (8). Inflammation in response to infection
with C. pneumoniae could stimulate the processing and deposition of amyloid in the CNS
(40).
Research by Little, et al (2004) developed a mouse model to dete1mine whether
infection with C. pneumoniae could induce neuropathology similar to what is seen in
sporadic AD. Non-transgenic BALB/c mice were infected with C. pneumoniae, which
induced AD-like pathology in the absence of predisposing genetic factors. The organism
was found in the olfactory epithelia as well as the olfactory bulbs. This finding suppmis a
nasal route of transmission into the CNS. Amyloid deposits that resembled human AD
plaques were also found. An inflammatory response was detennined by the detection of
activated astrocytes, some of which co-localized with the amyloid deposits (40). The
reactive astrocytes may be responding to the amyloid deposits or to the C. pneumoniae
antigen directly. Inflammation may stimulate the processing of amyloid, as well as inhibit
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the replication of C. pneumoniae (40). However, activated glial cells may also have
neurotoxic effects. Pro-inflammatory mediators released by activated glial cells could
lead to CNS injury (18).
Research into inflammatory processes in AD discovered that microglia in the AD
brain express major histocompatibility complex type II (MHCII) cell surface glycoprotein

(18). However, microglia fi-om non-demented (ND) brains showed substantially
decreased MHCII expression (18). Additionally, when exposed to beta amyloid deposits
in vitro, cultured AD and ND microglia show increased MHCII immuno-reactivity. This
suggests that exposure to beta amyloid leads to microglial activation, and is a cmcial step
in the initiation of inflatmnation seen in AD (18).
Beta amyloid was once believed to have no nmmal physiological function.
However, it was discovered that this peptide actually acts as a ligand for different
molecules and receptors that respond to enviromnental stressors (41). Beta amyloid
belongs to a group of antimicrobial peptides (AMPs), which function in the innate
immune system, and can respond to both Gram-negative and Gram-positive bacteria (41) .
Research by Soscia et al (41) discovered that the CNS could initiate a response to foreign
pathogens tlu·ough AMPs and the innate immune response. Beta amyloid may act as part
of an immune response to clear C. pneumoniae infection fi-om the CNS . However, as an
intracellular bacterium, C. pneumoniae can remain viable in host cells for prolonged
peliods by evading lysosomal degradation (8). The persistent state of this organism, along
with clu·onic reactivation, disrupts the balance of beta amyloid deposition and clearance
that was established in the amyloid cascade hypothesis (11). C. pneumoniae may be the
initial stimulus for beta amyloid production. However, the unique characteristics of tllis
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organism lead to an unresolved infection and, subsequently, chronic inflammation. This
may lead to production and deposition of amyloid and AD pathology.
The mechanism by which C. pneumoniae enters the CNS is still unknown. One
hypothesis states that this organism may infect monocytes in the lungs and spread the
infection through the peripheral circulation to the brain through the BBB (29). Research
by Macintyre et al (2003) utilized i1mnunohistochemistry to identify C. pneumoniae in
the brain blood vessels as well as in the lumen of these vessels in AD patients (42).
Additionally, C. pneumoniae was identified at the level of BBB microvasculature. This
organism was shown to infect human brain endothelial cells (HBMECs), which led to
increased expression of surface adhesion molecules VCAM-1 and ICAM-1. Additionally,
infection of monocytes with C. pneumoniae led to down regulation of occludin, the tight
junctional protein, at 72 hours post infection. These changes increased the probability for
transmigration of infected monocytes into the brain (29, 42).
Another possible route of transmission is through the olfactory pathway. C.
pneumoniae is a respiratory pathogen, giving it a direct cmmection to the olfactory
neuroepithelium of the nasal olfactory system (29). PCR analysis ofbrain tissue
discovered C. pneumoniae genetic material in these structures. The infection may then
progress to the olfactory bulbs, and transport to the entorhinal cmtex, hippocampus and
temporal cmtex, which interestingly, is also where some of the earliest pathology is
observed in AD (29). The role of C. pneumoniae in inflammatory diseases provides
further support for the hypothesis that infection with this organism can cause an
inflatmnatory response, leading to AD-like pathology and, eventually, symptomatic AD.
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1.8 Dissemination of C. pneumoniae From the Site of Primary Infection
Although debated, the association between C. pneumoniae and diseases such as
MS, AD and atherosclerosis, provide evidence that this bacterium can disseminate
systemically and cause infection in many areas of the body. C. pnewnoniae may use the
vasculature to disseminate. This organism was found in the spleen, aorta, and abdominal
lymph nodes, supp01iing that it can disseminate via monocytes to sites distant from
primary infection through the vasculature (30). The discovery of chlamydia in synovial
fluid of patients with ReA also suggests that monocytes may be involved in carrying tllis
organism to the joints distant from the initial infection (33). Immunohistochemical
staining found cells infected with chlamydia associated with blood vessels in the brain
(7, 29). The ability of this organism to cause a persistent infection in peripheral blood

monocytes (PBMCs) may fmiher enable these cells to cross the blood-brain batTier. In an
in vitro model, infection with C. pneumoniae caused human brain micro-vascular
endothelial cells (HBMECs) to enhance expression of surface adhesion molecules ICAM1 and VCAM-1 and led to a three-fold increase of infected monocytes through the
infected ban·ier in relation to uninfected monocytes through an uninfected endothelial
barrier. This suggests that infection of monocytes and micro-vascular endothelial cells
with C. pneumoniae may facilitate increased entry of C. pneumoniae into the CNS from
the systemic circulation (29). The ability of this organism to disseminate to sites distant
from that of the primary infection and to elicit a chronic inflmmnatory response, along
with the previous research confinning C. pneumoniae in AD brain tissue, supp01i a role
of C. pneumoniae infection in the development of AD-like pathology.
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1.9 Chlamydia muridarum and AD-like Pathology
To answer the question if AD-like pathology is specific to infection with C.
pneumoniae, we utilized C. muridarum (MoPn), a mouse adapted pneumonitis

genetically similar to C. trachomatis. However, unlike C. trachomatis, which infects the
genital tract, MoPn infects the respiratory tract, making it more similar to C. pneumoniae
in terms of the location of infection (43) In a 2004 study by Little, et al, C. pneumoniae
was isolated from human AD brain tissue and intranasally inoculated into BALB/c mice.
BALB/c mice were chosen because they are susceptible to C. pneumoniae infection and
can establish a chronic infection. These mice are also non-transgenic, indicating that they
do not have any human genes making them susceptible to early development of AD
pathology. Mice were sacrificed at 1, 2 and 3-month post infection and analyzed for
chlamydia antigen and amyloid burden using immunohistochemistry and light
microscopy. This produced a progressive pathology in the brains ofBALB/c mice (40).
In another study conducted by Little, et al, a laboratory strain of C. pneumoniae (AR39)
was introduced intranasally into BALB/c mice using the same procedure as the 2004
study. However, the laboratory isolate produced a transient pathology (44).
To determine if this pathology is specific only to C. pneumoniae, an in vivo
passaged strain of C. muridarum and a laboratory strain of C. muirdarum was introduced
intranasally into the brains ofBALB/c mice. Results indicated there was no significant
difference between the two isolates of C. muridarum. However, titer positive mice
showed a greater burden of chlamydia antigen and amyloid deposition than titer negative
mice. The cunent research will analyze glial cell activation in response to chlamydia
infection and amyloid burden.
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1.10 Objectives and Hypothesis
Based on the previous work indicating that infection with C. muridarum, a mouse
variant of chlamydia, leads to AD-like pathology, we hypothesize that
immunohistochemical analysis will indicate that infected brain tissue will have greater
glial cell burden in C. muridarum infected mice relative to titer negative C. muridarum
infected tissue.

The focus of this research is to determine if astrocytes are activated in brain tissue
of mice infected with C. muridarum. Immunohistochemistry and microscopy will be used
to determine if glial cells are more abundant in the infected mouse tissue. Mice infected
with C. m.uridarum displayed chlamydia antigen and amyloid deposits in the brain tissue.
BALB/c mice were intranasally infected with various known concentrations of C.
muridarum isolates, plagued in vivo passaged C small Weiss (CSW) and plagued stock

mouse pneumonitis Weiss (MoPn Weiss).
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2. Materials and Methods

2.1 Chlamydia muridarum
Two isolates of Chlamydia muridarum were used to intranasally infect BALB/c
mice. Chlamydia muridarum is a mouse variant of Chlamydia trachomatis. C small
Weiss (CSW) and mouse pneumonitis Weiss, (MoPn Weiss) are two different isolates of
C. muridarum that were used to infect different experimental groups of mice. C small

-w eiss is an isolate ofMoPn that was passaged in the urogenital tract of mice 3 sequential
times to increase its vimlence. MoPn Weiss is a plaque pmified, presumed monoclonal
stock isolate.

2.2 Infection of Mice and Tissue Preparation
Mice were intranasally infected with either C small Weiss or mouse pneumonitis
Weiss in the lab of Dr. Kyle Ramsey at Midwestern University in Chicago. Group A
mice were intranasally infected with 1 x 102 or 1 X 10 5 IFU's ofC small Weiss. Group B
mice were intranasally infected with 1 x 10 1 or 1 x 10 5 IFU of MoPn Weiss (Tables 1 &
2). Mice were sacrificed 60 days post infection, brains were removed and immersion
fixed in 4% paraformaldehyde and provided to this research group. Brain tissue was
embedded in paraffin, and coronally serial sectioned at 7-10 micron thickness.
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Table 1: C Small Weiss (MoPn in vivo) Experimental Group
Name

C. muridarum
Isolate

Inoculum
(IFU)

Duration of Infection

Titer

3A6

csw

100

60 days

Negative

3A8

csw

100

60 days

Negative

6A4

csw

100,000

60 days

1:5120

6A6

csw

100,000

60 days

1:10240

6A7

csw

100,000

60 days

1:5120

6A8

csw

100,000

60 days

1:5120

Table shows experimental design for the CSW group. Mice were intranasally infected with either 100 or
100,000 IFU's of CSW antigen. Seroconversion titers of animals were taken to detennine if infection was
established.

Table 2: Mouse Pneumonitis Weiss (MoPn Stock Solution) Experimental Group
Name

C.muridarum
Isolate

Inoculum
(IFU)

Duration of Infection

Titer

2B1

MoPn Weiss

10

60 days

Negative

6B1

MoPn Weiss

100,000

60 days

1:10240

6B5

MoPn Weiss

100,000

60 days

1:20480

6B6

MoPn Weiss

100,000

60 days

1:20480

6B8

MoPn Weiss

100,000

60 days

1:20480

6B9

MoPn Weiss

100,000

60 days

1:10240

6B10

MoPn Weiss

100,000

60 days

1:10240

Table shows experimental design for the MoPn Weiss group. Mice were intranasally infected with either 10
or 100,000 IFU's ofMoPn Weiss antigen. Seroconversion titers of animals were taken to detemline if
infection was established.
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2.3 Mouse Brain Tissue
A total of 12 coronal brain sections were immunolabeled per mouse. Ten sections
were labeled with Glial fibrillary acidic protein (GF AP) (Cat #180063) specific antibody
and two sections did not receive primary antibody and were used as a negative control. In
order to sample from areas throughout the brain, serial sections were selected every 70100 microns from rostral (bregma 0 mm, yellow 0) to caudal (bregma -4.82mm, blue 4)
(Figure 2).

Figure 2: Anatomic Location of Representative Coronal Sections
Top itnage represents the area of the brain where coronal sections were chosen every 7 to 10
microns. Sections rostral (red circles) to bregma (yellow circle) and caudal to bregma (blue
circles) are displayed. Panel B displays particular regions of interest, related to Alzheimer's
disease. Images were taken from the Mouse Brain Library (The Mouse Brain Library - Search the
library. (n.d.). Retrieved July 24, 2015.)
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2.4 Antibodies
Mouse brain tissue was previously immunolabeled for the presence of Chlamydia

muridarum utilizing a mouse monoclonal antibody. Beta amyloid protein was detected
utilizing a rabbit polyclonal antibody sc-9129 and a mouse monoclonal antibody 6E1 0
specific for amyloid antigen. The primary antibody specific for GF AP utilized to detect
glial cells was rabbit anti-GFAP (Invitrogen, Fredelick, MD) at a stock concentration of
151 .67 mg/L and was used at a working dilution of 1:100. To visualize the respected
antigen alkaline phosphatase conjugated goat anti-rabbit lg secondary antibody (Life
Technologies, Carlsbad, CA) was utilized at a concentration of 1.25 micrograms/ml
(1 :400). Antibodies were diluted to working concentration using 2% fetal bovine semm
and phosphate buffered saline.

2.5 Immunohistochemistry
Paraffin embedded mouse brain coronal sections were rehydrated plior to the
immunohistochemistry procedure. The rehydration consisted of 3 minute washes in
xylene (x3), followed by a series of graded alcohol dilutions: 100% ethanol for 3 minutes
(x2), 90% ethanol for 3 minutes (x1), 70% ethanol for 3 minutes (x1) (Electron
Microscopy Sciences, Fmi Washington, PA). Next, slides were washed in sterile filtered
DI H 2 0 for 3 minutes (x2). Slides were then placed in Citra antigen retrieval buffer
(BioGenex, San Roman, CA) and steamed at high pressure for 20 minutes at 120 degrees
Celsius in a 2010 Retreaver (Pick Cell Laboratories, Amsterdam, Netherlands). Slides
remained in antigen retrieval buffer overnight at room temperature.
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On day 2, slides were removed fi:om antigen retrieval buffer and washed with
phosphate buffered saline pH 7.4 (PBS) for 5 minutes (x3). Next, Alkaline Phosphatase
Horseradish Peroxidase was applied to slides for 5 minutes to quench endogenous
enzymatic activity. Slides were washed again, 5 minutes with PBS (x3).
Next, slides were blocked 15 minutes (x 1) with 2% heat inactivated fetal bovine
semm (FBS) (Mediatech, Herndon, VA) in PBS. Primary antibody rabbit anti-GFAP or
blocking buffer (2° group only) were applied to conesponding sections and placed in a
humidified chamber at 37° C for 90 minutes. Slides were then washed 5 minutes (x3)
with PBS and blocked 15 minutes (x2) with 2% FBS/PBS. Goat anti-rabbit Ig secondary
antibody was applied to each slide and then incubated for 60 minutes in a humidified
chamber at 37° C.
After the second incubation, slides were washed for 5 minutes (x3) with sterile
filtered molecular grade DI water (DI H2 0). Slides were developed for 15 minutes using
purple one component (BioFX, Eden Prailie, MN). Next slides were washed with DI H 2 0
5 minutes (x3) and PBS 5 minutes (xl), followed by counterstaining with acidified
Ranis's Hematoxylin (Mercury free) applied for 1 minute. The slides were rinsed with
DI H2 0 then washed with PBS for 5 minutes to produce a color change. Finally slides
were washed 5 minutes (x3) with DI H 2 0 then wiped down and air-dried. Once dry,
slides were mounted with Glycergel mounting media (Dako) and cover slipped.

2.6 Microscopic Analysis and Quantification of Glial Cell Number
Tissue was examined using lOx ocular and 4x and lOx power objectives on a
Nikon Eclipse 50i microscope. Images were taken of four quadrants on each section at
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lOx power objective (upper left, lower left, upper right, lower right). bnages were
captured using NIS-Elements F 2.20 and imaging systems software using a Nikon Digital
Sight DS-DM Camera. ImageJ software was used to analyze captured images to quantify
GF AP-positive immunolabled glial cells
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3. Results

3.1 Experimental infection of BALB/c mice
BALB/c mouse brain tissue was analyzed at 60-day post infection to determine
whether activated astrocytes were present. A total of 13 mouse brains were analyzed; 6
fi:om the intranasal infection with C small Weiss with 2 controls and 4 expelimentals and
7 from the intranasal infection with mouse pneumonitis Weiss with one control and 6
experimentals.

3.2 Analysis of GFAP specific labeling inC small Weiss
The C small Weiss group (n=6) consisted of2 titer negative controls that did not
seroconvert, indicating that an infection was not established, and 4 titer positive mice
(titers 1:5120 and 1:10240). A comparison of the dentate gyrus, an area that displays
pathology in AD, displayed activated glial cells in the titer negative, 1:5120 titer positive,
and 1:10240 titer positive groups (Figure 3 A, B, C). The entorhinal cmiex (EC), one of
the first areas affected in AD, showed activated glia in the titer negative group and the
1:10240 titer group, but is not as abundant in the I :5120 titer group (Figure 4 A, B, C). A
compalison of the thalamus shows substantial glial cell quantity across the three groups
(Figure 5 A, B C).

3.3 Analysis of GFAP specific labeling in mouse pneumonitis Weiss
The mouse pneumonitis group (n=7) consisted of one titer negative infected
mouse and 6 titer positive infected mice (titer 1:10240 and 1:20480). A comparison of the
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dentate gryus displayed activated glial cells in all three groups (Figure 6 A, B, C). The
entorhinal cortex displayed greater glial cell quantity in the titer negative and the 1:20480
titer group compared to the 1:10240 titer group. However, some glia are still observed in
the 1: 10240 titer group. (Figure 7 A, B, C). A comparison of the thalamus displayed great
glial cell amounts across the titer negative, 1:20480 and 1:10240 titer groups (Figure 8 A,
B, C).

3.4 Analysis of astroglia burden: C small Weiss (CSW)
A total of 10 slides per mouse were immunolabeled for activated astroglia using
GF AP labeling antibody and analyzed using light microscopy (See Materials and
Methods). Two mice in the C small Weiss (mouse pneumonitis in vivo) group were given
an infectious dose of 102 IFU and were titer negative for seroconversion, with glial cell
counts of 224 and 612 respectively (Figure 9). One mouse was titer negative for
seroconversion in the mouse pneumonitis Weiss group and therefore was grouped with
the two-titer negative mice in the C small Weiss group. The titer negative mice had a
mean glial cell count of 421 with a standard deviation of 194.07 (Table 3 and Table 4).
An infectious dose of 105 IFU was given to the remaining mice in the C small Weiss
group (6A6, 6A4, 6A7, 6A8) One mouse was titer positive for seroconversion with a titer
of 1:10240 and a glial cell count of 483. Three mice were titer positive for seroconversion
with a titer of 1:5120, glial cell counts of 186, 349, and 609 respectively (Figure 9), with
a mean glial count of381.33 and a standard deviation of213.35 (Table 3).
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3.5 Analysis of astroglia burden: mouse pneumonitis Weiss

A total of 10 slides per mouse were immunolabeled for activated astroglia and
analyzed using light microscopy (See Materials and Methods). One control mouse in the
mouse pneumonitis stock group was given an infectious dose of 102 IFU and was titer
negative for seroconversion with a glial cell count of 427 (Figure 10) (Table 4). The titer
negative mice in both groups were grouped together with a mean glial cell count of 421
and a standard deviation of 194.07 (Table 3 and Table 4). The remaining mice were given
an infectious dose of 105 IFU. Three mice were titer positive for seroconversion with a
titer of 1:10240 and glial cell counts of304, 318, and 405 respectively (Figure 10), with a
mean glial count of 342.33 and a standard deviation of 54.72 (Table 4). Three mice were
titer positive for seroconversion with a titer of 1 :20480 and glial counts of 809, 845 and
2034 (Figure 10), with mean glial count of 1229.33 and a standard deviation of697.09
(Table 4).

3.6 Analysis of amyloid deposits: C small Weiss

Previous work was done to detennine amyloid pathology in the C small Weiss
group. A total of20 slides per mouse were i1mnunolabeled for beta amyloid and analyzed
using light microscopy. Two mice were titer negative mice and did not seroconve1i and
displayed an amyloid burden of2 and 4 deposits, respectively (Table 3) (Figure 9). Tlu·ee
mice seroconve1ied with a titer of 1:5120 and had amyloid deposits ranging from 10 to
112 (Table 3) (Figure 9). One mouse seroconverted with a titer of 1:10240 and had an
amyloid burden of 52 deposits (Table 3) (Figure 9)
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3.7 Analysis of amyloid deposits: mouse pneumonitis Weiss
Previous work was done to determine amyloid pathology in the mouse
pneumonitis Weiss group. A total of20 slides per mouse were immunolabeled for beta
amyloid and analyzed using light microscopy. One mouse was titer negative, indicating
that it did not seroconvert and had an amyloid burden of2 deposits (Table 4) (Figure 10).
Tlu·ee mice seroconvetted with a titer of 1:10240 and had amyloid deposits ranging from
13 to 23. Three mice seroconvetted with a titer of 1:20480 and had amyloid deposits
ranging fi·om 4 to 9 (Table 4) (Figure 10).

3.8 Analysis of C muridarum antigen: C small Weiss
The presence of C. muridarum antigen was previously determined in the C small
Weiss group. A total of 3 0 slides per mouse were immunolabeled for C. muridarum and
analyzed using light microscopy. Two mice were titer negative mice indicating they did
not seroconvett and had a C. muridarum antigen burden of 1 and 21 , respectively (Table
4) (Figure 11). Tlu·ee mice seroconverted with a titer of 1:5120 and had C. muridarum
antigen ranging fi'om 5 to 121 (Table 4) (Figure 11 ). One mouse seroconverted with a
titer of 1:10240 and had a C. muridarwn antigen burden of 43 (Table 4) (Figure 11).

3.9 Analysis of C muridarum antigen: mouse pneumonitis Weiss
C. muridarum antigen burden was previously detennined in the mouse

pneumonitis Weiss group. A total of30 slides per mouse were immunolabeled for C.

muridarum and analyzed using light microscopy. One mouse was titer negative,
indicating that it did not seroconvett and had a C. muridarum antigen burden of2 (Table
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4) (Figure 12). Three mice seroconvelied with a titer of 1:10240 and had C. muridarwn
antigen ranging from 29 to 186 (Table 4) (Figure 12). Three mice seroconverted with a
titer of 1:20480 and had C. muridarum antigen ranging from 0 to 10 (Table 4) (Figure
12).

3.10 Summary of Results
A total of 13 BALB/c mouse brains were analyzed for astrocyte specific labeling.
Mice were inoculated with either the C small Weiss (n=6) or mouse pneumonitis Weiss
(n=7) variant of C. muridarum and sacrificed at the 60-day time point. Semiquantitative,
immunohistochemical and microscopic analysis revealed great vmiability in glial cell
specific labeling in mice intranasally inoculated with either isolate of C. muridarum.
Glial cell labeling ranged from 186 to 612 for the C small Weiss group and 304 to 2034
for the MoPn group. The greatest glial cell quantity between the titer negative controls
and the titer positive experiments was seen in mice intranasally inoculated with the
mouse pneumonitis Weiss variant of C. muridarum. The mean glial cell count of this
group was 427 for the titer negative group, 342.33 for the 1:10240 titer positive group,
and 1229.33 for the 1:20480 titer positive group, respectively. This indicates an
approximate 3-fold increase between the titer negative group and the titer positive
1:20480 experimental group (Table 4). The C small Weiss group displayed less than a
10% difference in glial cell amount between the two groups. The mean glial cell count of
this group was 418 for the titer negative control, 3 81.33 for the 1:5120 titer positive
group, and 438 for the 1:10240 titer positive group (Table 3).
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Figure 3 GFAP specific labeling of the dentate gyrus in CSW group tissue. 3A represents titer negative
seroconversion tissue. 3B represents tissue with I :5I20 titer positive seroconversion. Figure 3C represents
tissue with I: I 0240 titer positive seroconversion. GF AP specific labeling appears dark purple/black. Mag
bar represents I 00 microns.
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Figure 4 GF AP specific labeling of the entorhinal cortex in CSW group tissue. 4A represents titer negative
seroconversion tissue. 4B represents tissue with 1:5120 titer positive seroconversion. Figure 4C represents
tissue with 1: 10240 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag
bar represents 100 microns.
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Figure 5 GF AP specific labeling of the thalamus in CSW group tissue. SA represents titer negative
seroconversion tissue. SB represents tissue with 1:5120 titer positive seroconversion. Figure SC represents
tissue with 1: 10240 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag
bar represents 100 microns.
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Figure 6 GF AP specific labeling of the dentate gyrus in MoPn group tissue. 6A represents titer negative
seroconversion tissue. 6B represents tissue with 1: 10240 titer positive seroconversion. Figure 6C represents
tissue with 1:20480 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag
bar represents 100 microns.
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Figure 7 GFAP specific labeling of the entorhinal cortex in MoPn group tissue. 7A represents titer negative
seroconversion tissue. 7B represents tissue with 1: 10240 titer positive seroconversion. Figure 7C represents
tissue with 1:20480 titer positive seroconversion .. GF AP specific labeling appears dark purple/black. Mag
bar represents 100 microns.
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Figure 8 GFAP specific labeling of the thalamus in MoPn group tissue. 8A represents titer negative
seroconversion tissue . 8B represents tissue with 1: 10240 titer positive seroconversion. Figure 8C represents
tissue with 1:20480 titer positive seroconversion . . GF AP specific labeling appears dark purple/black. Mag
bar represents 100 microns.
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C small Weiss
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3A6
0
100
224
421
194.07
3A8
0
100
612
1
5120
100,000
6A4
186
5
5120
100,000
6A7
349
381.33
213.35
117
6A8
5120
100,000
609
121
6A6
100,000
483
43
Table 3: Glial cell totals for C small Weiss in vivo group. Mean values represent average glial cell count for
all brains with the same seroconversion titer. Titer negative represents mean value for C small Weiss (n=2)
and mouse pneumonitis Weiss (n= l). Nomenclature for individual mice (Brain) is as follows: Infectious
dose received intranasally, isolate of C. muridarum, identifier for individual mouse. For example, mouse
3A6 was the sixth mouse (6) that received 100 IFUs (3) ofC small Weiss (A)
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4
112
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mouse
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•

:
281
6810
681
689
686
688
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•
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0
10240
10240
10240
20480
20480
20480

10
100,000
100,000
100,000
100,000
100,000
100,000

427
304
318
405
809
845
2034

421

1229.33

.07

697.09

Table 4: Glial cell totals for mouse pneumonitis Weiss group. Mean values represent average glial cell
count for all brains with the same seroconversion titer. Titer negative represents mean value for C small
Weiss (n=2) and mouse pneumonitis Weiss (n= l). Nomenclature for individual mice (Brain) is as follows:
Infectious dose received intranasally, isolate of C. muridarum (A indicates C small Weiss, B indicates
mouse pneumonitis Weiss), identifier for individual mouse.
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CSW Comparision of Glial Cell Count and Amyloid Deposits
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Figure 9: Analysis of astroglia burden and amyloid deposits: C small Weiss (CSW).
Y -axis represents amyloid burden per mouse. X-axis represents glial cell count per
mouse.
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Figure 10: Analysis of astroglia burden and amyloid deposits: Mouse pneumonitis Weiss
(MoPn). Y-axis represents amyloid burden per mouse. X-axis represents glial cell count
per mouse.
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Figure 11: Analysis of C. muridarum antigen: C small Weiss. Y-axis represents C.mu
antigen per mouse. X -axis represents glial cell count per mouse.
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MoPn Comparison of Glial Cell Count and C. muridarum Antigen
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Figure 12: Analysis of C. muridarum antigen: Mouse pneumonitis Weiss. Y-axis
represents C. mu antigen per mouse. X-axis represents glial cell count per mouse.
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4. Discussion
The extracellular deposition of beta amyloid, neurofibrillary tangles and activated
glial cells leading to an inflammatory cascade are all the initiating events that eventually
lead to the neurodegeneration that is seen in AD. The goal of this work was to determine
glial cell response to infection with Chlamydia muridarum and the relationship relative to
deposited beta amyloid. It was hypothesized that as amyloid deposits and chlamydia
antigen burden increases, glial cell count will also increase. A slight inverse relationship
was observed between glial cell count and amyloid deposits in the C small Weiss group.
However, this trend is not as prominent as that observed in the mouse pneumonitis group.
This finding supp01is the hypothesis that the in vivo passaged strain of C. muridarum is
more antigenic and stimulates the host immune response more than the mouse
pneumonitis Weiss stock isolate. In the 2004 study by Little, et al, C. pneumoniae
isolated from human AD brain tissue and reintroduced intranasally into the brains of nontransgenic BALB/c mice displayed a progressive AD-like pathology (40). As the
infection advanced, the amyloid deposits in the brain increased in number and size (40).
This con·elates with the data seen in the C small Weiss group. As the titer amount
increased, the amount of amyloid deposits increased while glial cell counts follow a slight
downward trend. It is hypothesized that the glial cells are not phagocytosing the amyloid
and becoming activated, therefore this would allow the pathology to progress. In a study
by Krabbe, et al, (20 13) an inverse con·elation was detected between amyloid plaque
burden and microglia phagocytic activity. When stimulated with TNFa, microglia
displayed a down-regulation of receptors involved in beta amyloid binding and
degradation (45).
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In this study, an inverse relationship was observed between glial cell count and
amyloid deposits in the mouse pneumonitis Weiss group. As glial cell counts increased,
amyloid deposits decreased. This finding is consistent with previous research. Astrocytes
not only adhere to beta amyloid, but findings indicate they may also degrade it (46-48).
In human AD brain tissue, it was noted that beta amyloid was present in astrocytes
sunounding amyloid plaques (48). Hippocampal brain tissue that was incubated for 24
hours with astrocytes displayed 40% less area occupied by beta amyloid than untreated
tissue (48). Astrocytes, along with microglia, work to phagocytose the beta amyloid and
clear it from the CNS. These glial cells become more abundant and activated during tllis
process, leading to a series of changes refened to as astrogliosis (47). However,
activation of glial cells can promote neuronal damage through the production of proinflammatory cytokines. The release of these cytokines can cause dysfunction of nerve
tenninals and loss of synapses, leading to memory decline and eventually neuronal death
in late stages of AD (19) .
Mouse pneumonitis Weiss, the stock isolate of C. muridarum, is hypothesized to
be less virulent than the in vivo passaged C small Weiss isolate. When comparing a stock
isolate and an in vivo passaged isolate of C. muridarum, Ramsey et al indicated a
significant virulence difference in vivo as well as different growth characteristics in vitro
(49). They discovered a greater virulence of the in vivo passaged isolate of mouse
pneumonitis Weiss when compared to a stock isolate of the organism. A study by Little et
al (2014) dete1mined infection with the stock isolate of C. pneumoniae results in a
transient infection. Cpn antigen peaked at the one-month time point followed by a peak in
beta amyloid at the two-month time point. Amyloid deposits reduced as Cpn antigen
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burden reduced over time (44) . This is in contrast with the in vivo passaged isolate, which
resulted in a progressive pathology over time (40) . These results suggest that the in vivo
passaged isolate of Cpn is more virulent than the stock isolate of Cpn.
For both isolates, the trend follows that when there are fewer glial cells, amyloid
is more abundant. Additionally, as glial cell counts increased, there is less amyloid
deposited. This finding is supported by previous research, which supports that glial cells
phagocytose beta amyloid, resulting in activation and an increase in glial cell number and
a reduction ofbeta amyloid (46-48, 50).
The in vivo passaged C small Weiss isolate of C. muridarum displayed a positive
trend when comparing chlamydia antigen to glial cell counts. As glial cell count
increased, the amount of C. muridarum antigen also increased. However, for the stock
isolate of C. muridarum, mouse pneumonitis Weiss, as glial cell count increased, the
amount of C. muridarum antigen decreased. This fuliher supports the hypothesis that the
in vivo passaged isolate of C. muridarwn is more virulent than the stock isolate. While
testing the vimlence of the two strains, Ramsey et al detennined that mice inoculated
with the in vivo passaged isolate of C. muridarum were likely to establish a secondary
infection regardless if the stock isolate or the in vivo passaged isolate caused the primary
infection (49). Additionally, seroconversion rates were higher with low dose infections of
both the urogenital and the respiratory tract with the in vivo passaged isolate when
compared to the stock isolate. This indicates that the in vivo passaged isolate is better able
to establish infection (49). This suppmis the hypothesis that the in vivo passaged C small
Weiss is better able to establish an infection when introduced intranasally into BALB/c
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mice and, due to the high virulence of the organism, it is difficult for the glial cells to
clear it fi:om the CNS.
Selective vulnerability in regions that are typically implicated in AD was not
observed in GFAP specific labeling in either the C small Weiss (Figure 3) or the mouse
pneumonitis Weiss group (Figure 4). However, this would not be atypical as the 60-day
time point is relatively early to see an increase in astrocyte specific GF AP labeling in
these areas. Studies using transgenic mouse models indicate an increase in activated
astrocytes; however, enhancement of GF AP-positive astrocyte labeling is not seen at this
early time point (51). A study by Mastrangelo et al utilized triple transgenic mice and
observed GF AP-positive astrocyte labeling at nine months of age in the entorhinal cmiex,
but did not observe robust labeling until the 18-month and 26-month time points (52).
In summary, the cunent mouse model comparing glial cell activation and AD-like
pathology indicates a virulence difference between the two isolates of C. muridarum.
There is a greater chlamydia antigen burden and amyloid deposit burden in the titer
positive C small Weiss group relative to the titer positive mouse pneumonitis Weiss
group. The greatest documented difference with respect to burden was observed for
amyloid between the two C. muridarum isolates, with MoPn displaying a four fold
increase relative to titer negative mice and CSW displaying a 15-fold increase. A study
by Rank: et al (20 12) measured the virulence oftwo isolates of C. trachoma tis in the
conjunctiva of guinea pigs. They demonstrated that the attenuated AZ2 variant was
slower growing and unable to elicit a strong inflammatory response compared to the
"wild-type" SP6 isolate. This was due to a defect of AZ2 making it unable to activate the
TLR2 receptor in the inflammatory pathway (53). In a similar study by Yeruva et al

46

studying the ability of the chlamydia! variants to ascend the genital tract, IL-8 levels were
lower in secretions of AZ2 infected animals than SP6 infected animals. AZ2 was also not
able to ascend the genital tract to the oviduct as readily as SP6, which may be related to
the inability of AZ2 to elicit a strong inflammatory response (54). This is consistent with
the cmTent hypothesis that, in general, the in vivo passaged isolates of C. muridarum are
more virulent. Thus, CSW induced greater AD-like pathology than MoPn.
The amount of glial cell burden observed in this study was isolate specific. The
initial hypothesis proposed that glial cell burden would increase in response to chlamydia
infection and amyloid pathology. For CSW, as chlamydia antigen burden increased, glial
cell counts also increased. The relationship of glial cells and chlamydia antigen burden
differed from the initial hypothesis for MoPn. As chlamydia antigen burden increased,
glial cell counts decreased. The relationship of glial cells and amyloid burden also
differed from the initial hypothesis. There was inverse conelation between glial cell
count and amyloid deposit burden in the CSW group. There is a considerably greater
inverse conelation between glial cell count and amyloid deposit burden in the MoPn
group than that observed in the CSW group. Therefore, the relationship of glial cells with
amyloid and chlamydia antigen is isolate specific.

5. Future Directions

This study sought to detennine if AD-like pathology and chlamydia infection led
to an increase in activated astrocytes in the brains ofBALB/c mice. It was hypothesized
that as chlamydia antigen burden and amyloid deposit burden increased, the amount of
activated glia would also increase. This trend was seen in only the C small Weiss isolate
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of C. muridarum comparing glial cell count to chlamydia antigen burden. As chlamydia
antigen burden increased, the amount of activated glial cells decreased. As chlamydia
antigen burden increased in the mouse pneumonitis Weiss group, the amount of activated
glial cells also increased . For both groups, there was an inverse conelation between
amyloid burden and glial cell count. However, the presence of outliers in the small
sample size demonstrates the need for a larger number of animals. In addition it would be
beneficial to analyze glial cell activation at additional time points, including the 30-day
time point, 90-day time point, and 120-day time point. This would allow us to dete1mine
whether the strains we are working .with are inducing a chronic infection with progressive
pathology or a transient infection with transient pathology, both of which have been
observed in BALB/c mice infected with C. pneumoniae (40, 44). By increasing the
sample size and looking at different time points, a more conclusive conelation between
intranasal infection with C. muridarum, development of AD-like pathology, and
inflammation in mouse brain tissue can be established.
To determine if the in vivo passaged isolate of C. muridarum is more virulent that
the stock isolate, the use of cell culture would be beneficial. If the in vivo passaged isolate
of C. muridarum is, in fact, more virulent, it is hypothesized that it will replicate faster.
Previous studies observed that the main difference in virulence between two isolates of
chlamydia conelated with replication rate or "burst size" (49, 55). Higher replication
rates conespond to a greater ability to establish infection in the host, and therefore a
greater potentially damaging inflammatory response. A greater sample size with analysis
at various time points combined with cell culture of C. muridarum will provide more
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evidence that this organism can produce AD-like pathology and inflammation in the
brains ofBALB/c mice.
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